, Singapore

Daily Markets Briefing: STI down 1.5%

Index poised for a modest technical rebound.

According to OCBC Investment Research:

The rebound on Wall Street overnight is likely to provide some relief to the local bourse this morning; but caution is still expected to reign ahead of the key US job report tonight.

After plunging another 1.5% for the second consecutive session, the STI could be poised for a modest technical rebound around current levels today. However, we do not rule out potential selling into strength at higher levels.

For now, we have shifted the immediate support to the 3160 level (key troughs), with the next base lying at the 3100 key psychological level.

On the upside, 3240 (key support-turned-resistance) is now the immediate obstacle; followed by the 3270 minor support-turned-resistance.
 

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.


If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Top News

AI growth stalls as 78% cite weak data infrastructure
Confluent said firms are prioritising data streaming as they move AI projects from pilots into production.
Singapore emerges as key hub in Asia-Pacific’s next medtech wave
The city-state’s regulatory strength helps translate medical innovations into globally validated products.
Healthcare